

# **The Immune System's Interplay with Cancer and the Landscape of Immunotherapy**

**Li Lei, PhD**

**Bioinformatics Scientist in Lawrence Berkeley National Lab**

## **07/01/2025**

## **Abstract**

In the evolving landscape of oncology, liquid biopsy is emerging as a transformative tool for the detection of Minimal Residual Disease (MRD), offering a non-invasive method to identify the minute number of cancer cells that persist after treatment and often precede clinical relapse. By analyzing circulating tumor DNA (ctDNA) from a simple blood draw, these highly sensitive assays can detect MRD with remarkable lead time over conventional imaging, enabling a more dynamic and real-time assessment of treatment efficacy. This approach has demonstrated significant prognostic value across a spectrum of solid tumors—including colorectal, lung, and breast cancer—and hematological malignancies, where the presence of ctDNA post-treatment is a strong predictor of recurrence. While challenges in standardization, analytical sensitivity, and clinical validation remain, the ongoing integration of advanced bioinformatics and multi-omic strategies is paving the way for liquid biopsy-guided MRD assessment to become a cornerstone of personalized cancer care, allowing for early intervention and tailored therapeutic strategies to improve patient outcomes.

## **I. The Immune System's Response to Cancer: Surveillance and Evasion**

The human immune system possesses a remarkable, albeit imperfect, capacity to recognize and eliminate malignantly transformed cells, a process termed immune surveillance. This intricate defense mechanism is constantly challenged by the inherent adaptability of cancer cells, which evolve sophisticated strategies to evade immune detection and destruction. Understanding this dynamic interplay is fundamental to developing effective cancer therapies.

### **A. Immune Recognition of Malignant Cells**

The immune system's ability to identify cancer cells stems from their expression of specific antigens that distinguish them from healthy cells. This recognition often initiates with the detection of "danger signals" released by developing tumors, which are promptly sensed by components of the innate immune system.1 Furthermore, the inflammatory environment within a tumor, known as the tumor microenvironment (TME), promotes the accumulation of various immune cells at the site of malignancy, further facilitating recognition.2

Immune cells employ a multifaceted approach to counteract tumors. These strategies include the absorption and presentation of tumor antigens to other immune cells, the release of cytokines that activate and recruit additional immune components, and the direct destruction of tumor cells.2

Phagocytes, both professional cells like macrophages and immature dendritic cells, and non-professional cells such as fibroblasts and epithelial cells, are central to the initial recognition and engulfment of aberrant cells.2 Several surface molecules on tumor cells act as critical "eat-me" signals for these phagocytes. Phosphatidylserines, typically residing on the inner leaflet of cell membranes, translocate to the cell surface in apoptotic cells, signaling for their removal. Intriguingly, some tumor cells exhibit elevated levels of surface phosphatidylserines, thereby presenting themselves as targets for phagocytosis.2 Another pro-phagocytic signal is calreticulin, which is normally found intracellularly but is expressed on the cell surface under cellular stress. Surface calreticulin binds to the CD91 receptor on phagocytes, leading to the absorption of the target cell. While certain cancers overexpress surface calreticulin, normal cells maintain low levels and actively send anti-phagocytic signals via surface CD47 to prevent inadvertent destruction.2

Heat Shock Proteins (HSPs) also play a complex role in tumor recognition. Tumor cells frequently exhibit elevated expression of HSPs. Intracellular HSPs can paradoxically protect tumor cells from the stressful conditions of the microenvironment, posing a challenge for anti-tumor therapies. However, membrane-bound and extracellular Hsp70 exert a stimulating effect on the immune system.2 These proteins can bind intracellular antigen peptides, forming complexes that are subsequently presented on the cell surface, often following cell lysis. Antigen-presenting cells (APCs) possess surface receptors that capture these HSP-peptide complexes, internalize them, and then present the antigens to CD8+ T-cells, thereby promoting cytotoxic lymphocyte activity. Moreover, surface Hsp70 directly mediates the cytotoxic functions of Natural Killer (NK) cells, which recognize and lyse tumor cells expressing surface Hsp70. The CD94 receptor on NK cells is thought to be involved in this recognition, with Hsp70 acting as an activating signal, contrasting with the inhibitory signal provided by tumor cell surface HLA-E.2 The dual nature of Heat Shock Proteins, acting as both intracellular protectors for tumor cells and extracellular immune stimulators, presents a complex challenge and opportunity for therapeutic intervention. A broad therapeutic approach that indiscriminately inhibits HSPs could inadvertently remove their immune-stimulating effects while failing to adequately address their intracellular protective roles, or even enhance tumor survival by disrupting their immune-activating function. Therefore, future immunotherapies or combination strategies must consider this nuance, aiming to specifically neutralize the pro-survival intracellular HSP functions or enhance the immune-stimulating extracellular HSP functions, without inadvertently providing a survival advantage to the tumor. This necessitates highly targeted approaches, potentially focusing on specific HSP isoforms, their cellular localization, or the precise pathways they activate.

### **B. Key Immune Cells in Anti-Tumor Immunity**

The immune system orchestrates anti-tumor responses through the coordinated action of various cell types, broadly categorized into innate and adaptive immunity.

Innate Immune Cells: These cells provide the body's immediate, non-specific defense.  
Natural Killer (NK) cells are crucial components of the innate immune system, renowned for their ability to recognize and suppress cancer cell proliferation without prior sensitization or the requirement for Major Histocompatibility Complex (MHC) molecule expression on target cells.3 These lymphocytes constitute a significant fraction (5-20%) of peripheral blood lymphocytes and originate in the bone marrow, subsequently migrating to lymphatic organs such as lymph nodes, the spleen, and the thymus.3 NK cells eliminate cancer cells through several mechanisms, including direct lysis via the secretion of perforin and granzymes, antibody-dependent cell-mediated cytotoxicity (ADCC), and the release of cytokines like interferon-gamma (IFN-γ) that suppress tumor growth and angiogenesis.3 Their anti-tumor activity is initiated through the binding of activating receptors (e.g., NKp46, NKp30, NKp44, NKG2D) to specific ligands expressed on the surface of cancer cells.3  
Macrophages are professional phagocytes that play diverse roles within the TME, including the presentation of antigens to other immune cells.1

Dendritic Cells (DCs) are indispensable antigen-presenting cells (APCs) that initiate and coordinate adaptive anti-tumor immunity.5 They capture tumor-associated antigens (TAAs) and present them to T cells in draining lymph nodes, thereby activating cytotoxic T lymphocytes (CTLs) and promoting robust adaptive immune responses.5 Mature DCs are particularly effective at priming CTLs.5 The critical role of Dendritic Cells as a bridge between innate and adaptive immunity, coupled with their documented impairment by tumor-derived factors, reveals a key vulnerability in the anti-tumor immune response that cancer actively exploits. The innate immune system detects danger signals and stimulates APCs (including DCs) to process tumor antigens, which then travel to lymph nodes to inform adaptive lymphocytes.1 DCs are thus essential for initiating and coordinating anti-tumor immunity by presenting TAAs to T cells.5 However, their function is frequently and significantly impaired by tumor-derived factors, including microRNAs, which modulate DC maturation, antigen presentation, cytokine secretion, and survival, often promoting immune tolerance and tumor progression.5 If DCs, the "coordinators" of adaptive immunity, are compromised, the downstream activation of T cells, which are vital for direct tumor killing and immunological memory, will be severely hampered. This direct causal chain—tumor factors leading to DC impairment, which in turn compromises T cell activation—facilitates immune escape. Therefore, immunotherapeutic strategies should not only focus on activating T cells directly but also on restoring or enhancing DC function. Therapies aimed at counteracting tumor-derived factors that suppress DCs or directly promoting DC maturation and antigen presentation could significantly bolster the overall anti-tumor immune response, potentially making T-cell based therapies more effective.

Adaptive Immune Cells: These cells provide specific, memory-driven responses.  
T Lymphocytes (T cells) are central to adaptive immunity, which forms the foundation of immunological memory, enabling a rapid and precise response upon re-encountering a specific threat.1 T lymphocytes directly engage tumor cells, secreting cytotoxic enzymes to destroy them.1 Cytotoxic T Lymphocytes (CTLs), in particular, destroy target cells by triggering apoptosis. They release preformed perforins at the target cell surface, creating transmembrane holes, which allows granzymes to enter the cytosol and initiate an apoptotic cascade.1 T-cell activation is a two-signal process, requiring both the T-cell receptor (TCR) binding to a peptide-MHC molecule and a costimulatory signal, such as the binding of B7 on APCs to T cells.1 Both CD4+ and CD8+ T cells are critical in the elimination phase of tumor destruction.6  
B Lymphocytes (B cells) also contribute to anti-tumor immunity. Tumor-infiltrating B cells (TIL-B cells) within the TME secrete antibodies of various isotypes (mainly IgM, IgG, and IgA) that can recognize tumor cells.7 The frequent presence of serum autoantibodies in cancer patients suggests an association between autoimmunity and cancer, with these autoantibodies potentially serving as biomarkers for anti-tumor responses.7

**Table 1: Key Immune Cells and Their Roles in Anti-Tumor Immunity**

| Cell Type | Primary Role in Anti-Tumor Immunity | Key Mechanisms/Markers (brief) |
| :---- | :---- | :---- |
| Natural Killer (NK) Cells | Direct lysis of infected/cancer cells without prior sensitization | Perforin, Granzymes, ADCC, NKG2D |
| Cytotoxic T Lymphocytes (CTLs) | Direct killing of target cells via apoptosis | Perforin, Granzymes, FasL, MHC Class I |
| Helper T Cells (CD4+) | Coordinate immune responses, cytokine production | Cytokine secretion, TCR, MHC Class II |
| B Lymphocytes | Antibody production, antigen recognition | Antibody secretion, Tumor Antigen recognition |
| Dendritic Cells (DCs) | Antigen presentation, T cell activation | TAA capture, MHC presentation, Cytokine secretion |
| Macrophages | Phagocytosis, antigen presentation, cytokine production | Phagocytosis, Cytokine secretion |
| Regulatory T Cells (Tregs) | Immune suppression, maintaining tolerance | TGF-β, IL-10, FoxP3 |
| Myeloid-Derived Suppressor Cells (MDSCs) | Immune suppression, T cell inhibition | Arginase 1, iNOS, ROS, IL-10, TGF-β |
| Cancer-Associated Fibroblasts (CAFs) | Immune suppression, T cell exclusion, ECM production | Dense ECM, CXCL12, FAP |

### **C. The Cancer Immunoediting Concept: Elimination, Equilibrium, and Escape**

The interaction between the immune system and cancer is not a static battle but a dynamic evolutionary process, best described by the "cancer immunoediting" concept.6 This framework acknowledges that the immune system both protects against tumor development and, under certain conditions, can inadvertently promote tumor growth.8 The process unfolds in three distinct phases: elimination, equilibrium, and escape.

**Elimination Phase:** In this initial stage, the immune system actively detects and eliminates newly formed tumor cells before they become clinically apparent. This phase is synonymous with the original theory of tumor immune surveillance. Key immune cells, including Natural Killer (NK) cells, CD4+ and CD8+ T cells, macrophages, and granulocytes, work in concert to suppress malignant cells.3 Crucial molecular mediators in preventing tumor formation during this phase include interferon-gamma (IFN-γ) and perforin.6

**Equilibrium Phase:** If the immune system is unable to completely eradicate all tumor cells, a state of dynamic equilibrium may ensue. In this phase, the immune system effectively keeps tumor expansion in check, leading to a period of tumor dormancy where the tumor size remains relatively constant.1 This can be a prolonged period during which the tumor is present but does not progress clinically.

**Escape Phase:** This third and final phase occurs when tumor cells evolve beyond the immune system's capacity to control them. During this stage, tumor cells emerge that either exhibit reduced immunogenicity or develop other sophisticated mechanisms to evade immune destruction, ultimately leading to the appearance of clinically detectable tumors and progressive disease.1 This transition can be observed clinically, for example, in the progression from premalignant conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS) to multiple myeloma, where the shift signifies tumor escape.6 The "immunoediting" concept highlights the dynamic and evolutionary nature of cancer in response to immune pressure. The progression from elimination to equilibrium and ultimately to escape implies that tumors are not passive targets but actively adapt to evade immune surveillance. This continuous evolutionary process means that tumor cells are under selective pressure from the immune system, and those that develop effective evasion mechanisms are selected for survival and proliferation, leading to the escape phase. This dynamic nature suggests that a single, static therapeutic intervention might be insufficient for long-term disease control. Immunotherapies must account for this evolutionary capacity, perhaps by targeting multiple evasion pathways simultaneously, employing sequential therapies, or developing strategies that can adapt as the tumor evolves. This underscores the profound challenge of achieving durable remission and the potential for relapse due to the emergence of resistant clones.

Evidence supporting the immunoediting theory comes from both animal models and clinical observations. For instance, immunosuppressed patients exhibit a higher incidence of certain tumors, although the contributions of viral infections, cytotoxic drugs, and persistent inflammation in this context also require careful consideration.6

### **D. The Tumor Microenvironment (TME) and Immunosuppression**

The Tumor Microenvironment (TME) is a highly dynamic and complex ecosystem that profoundly influences tumor progression and immune responses.7 It comprises not only the tumor cells themselves but also a diverse array of cellular components, including stromal cells (e.g., fibroblasts, endothelial cells, neuronal cells), infiltrating immune cells, and non-cellular elements like the extracellular matrix (ECM) and interstitial fluid.11

The balance between pro-tumorigenic and anti-tumor factors within the TME critically dictates tumor growth.11 Cancer cells actively communicate with and can convert surrounding stromal cells into allies, thereby impacting various aspects of tumor biology and promoting their own survival and proliferation.11

The TME frequently exhibits characteristics that actively suppress anti-tumor immunity, creating a hostile environment for effector immune cells. This active suppression directly impedes the effectiveness of immune cells. The TME is often characterized by hypoxia (low oxygen levels) and a low pH (typically below 4), both of which directly suppress the activity of cytotoxic T lymphocytes (CTLs).10 Furthermore, metabolic alterations within the TME, such as glucose deprivation and cholesterol enrichment, exacerbate T cell exhaustion, rendering them less effective.10 Hypoxia can also lead to the upregulation of immune checkpoint molecules like PD-L1, further contributing to immune evasion.10 Cancer-associated fibroblasts (CAFs), a significant component of the stromal cells, produce a dense extracellular matrix (ECM). This physical barrier can effectively trap T cells in the stroma, preventing their access to the cancer cells themselves.12 Additionally, CAFs secrete CXCL12, a chemokine that actively excludes T cells in a CXCR4-dependent manner, further limiting their infiltration into the tumor core.12 The Tumor Microenvironment is not merely a passive site of tumor growth but an active, immunosuppressive entity that erects multiple barriers—physical, chemical, and cellular—to anti-tumor immunity. Specific elements like hypoxia and low pH directly suppress CTL activity 11, while the dense ECM and secreted CXCL12 from CAFs physically trap and exclude T cells.12 These are not just characteristics but active mechanisms that directly hinder immune cell function and access. This implies that effective immunotherapy may require strategies that directly target and remodel the TME in addition to activating immune cells. Approaches that break down the ECM, normalize pH and oxygen levels, or neutralize TME-derived suppressive factors could significantly improve immune cell infiltration, survival, and effector function, thereby enhancing the overall efficacy of immunotherapies. This suggests a critical need for combination therapies that address both the immune cells and their surrounding environment.

### **E. Mechanisms of Tumor Immune Evasion**

Despite the immune system's inherent surveillance capabilities, tumor cells are remarkably adaptable and develop diverse mechanisms to escape immune recognition and destruction. These strategies, collectively known as "immune evasion," are pivotal in understanding tumor recurrence and metastasis.5

One primary evasion tactic involves the **downregulation of tumor antigens and MHC molecules**. Cancer cells can reduce the expression of various surface antigens and Major Histocompatibility Complex (MHC) class I molecules, rendering them less visible and recognizable to immune cells, particularly T cells.9 This phenomenon, often referred to as "antigen loss" or "antigenic modulation," is frequently observed in rapidly dividing tumors due to their high mitotic rate and inherent genetic instability.1 However, the immune system has a compensatory mechanism: Natural Killer (NK) cells can specifically target and destroy cells that have absent or downregulated MHC-I expression, acting as a crucial backup defense.4

Tumors frequently achieve immune evasion through the **expression of immune checkpoint molecules** on their surface, such as Programmed Death-Ligand 1 (PD-L1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).9 These molecules interact with their corresponding receptors (e.g., PD-1 on T cells), sending inhibitory signals that effectively "turn off" T cells, thereby preventing their activation and function.10 This mechanism represents a critical regulatory component of the immune system, which cancer cells have hijacked to inactivate immune cells before they can eliminate the tumor.13 PD-L1 expression on tumor cells alone has been shown to potently inhibit CD8+ T cell cytotoxicity.14 The upregulation of PD-L1 can occur through various pathways, including structural alterations (amplifications, gains, and translocations of chromosome 9p24.1), activation of the JAK/STAT signaling pathway (induced by IFN-γ or increased IL-10), mutations in SOCS1 (a tumor suppressor), decreased levels of certain microRNAs (miRNAs), and Epstein-Barr virus (EBV) infection.15

Another significant evasion strategy is the **secretion of immunosuppressive cytokines**. Tumor cells can produce and secrete large quantities of cytokines such as Transforming Growth Factor-beta (TGF-β) and Interleukin-10 (IL-10).1 These cytokines directly suppress immune responses; for instance, TGF-β can inhibit T cell activation and proliferation, while IL-10 suppresses the production of pro-inflammatory cytokines.10

The TME is also characterized by the **recruitment and expansion of immunosuppressive cells** that actively limit the function of cytotoxic T cells and other anti-tumor immune cells.3 Regulatory T cells (Tregs) are a heterogeneous subset of CD4+ T cells that maintain immune homeostasis and self-tolerance. Within the TME, they constitute a significant suppressive population, inhibiting CD4+ and CD8+ effector T cells, NK cells, NKT cells, and APCs through the secretion of immunosuppressive cytokines (e.g., TGF-β1, IL-10, IL-35, Galectin-1) and the production of cytolytic factors like Granzyme A/B.12 Myeloid-derived Suppressor Cells (MDSCs) are immature myeloid progenitor cells that fail to differentiate and exhibit potent immunosuppressive properties. They contribute to the immunosuppressive TME by producing Arginase 1 (ARG1) and upregulating iNOS (which metabolize L-arginine, impairing T cell function) and by secreting IL-10 and TGF-β.12 Tumor-associated Macrophages (TAMs), while macrophages can generally be anti-tumor, often adopt an M2-polarized phenotype within the TME that actively promotes tumor growth, angiogenesis, fibrous stroma deposition, and metastasis. Their immunosuppressive mechanisms involve TGF-β production and the secretion of VEGF and CCL18.12 Cancer-associated Fibroblasts (CAFs), a type of stromal cell, suppress anti-tumor immune responses by physically restricting T cells through the production of a dense extracellular matrix and by secreting CXCL12, which excludes T cells from the immediate vicinity of cancer cells.12

The various immune evasion mechanisms employed by cancer cells are not isolated but form intricate, interconnected networks, creating reinforcing feedback loops that further entrench the immunosuppressive tumor microenvironment. For example, tumor cells secrete immunosuppressive cytokines like TGF-β and IL-10, which suppress immune responses and promote tumor growth.10 Simultaneously, immunosuppressive cells such as TAMs, MDSCs, and Tregs, which are recruited to and expanded within the TME, also produce these same immunosuppressive cytokines.12 This creates a clear feedback mechanism: tumor cells secrete immunosuppressive cytokines, which in turn recruit and activate immunosuppressive immune cells (Tregs, MDSCs, TAMs), and these recruited cells then secrete more immunosuppressive cytokines. This self-reinforcing cycle amplifies and maintains the immunosuppressive state of the TME. This complex interdependency implies that single-target therapies may be insufficient to break this entrenched immunosuppression. A more effective approach would involve multi-pronged combination therapies that simultaneously target multiple nodes within this network, addressing both the tumor's intrinsic evasion mechanisms and the TME's suppressive cellular and molecular components. This is crucial for overcoming resistance and achieving more profound and durable anti-tumor responses.

**Table 2: Mechanisms of Tumor Immune Evasion**

| Evasion Mechanism Category | Specific Mechanism/Molecule | Impact on Immune Response | Relevant Immune Cells Affected |
| :---- | :---- | :---- | :---- |
| Antigen Loss/Downregulation | Downregulation of MHC Class I/Tumor Antigens | Reduced recognition by T cells; NK cell activation (compensatory) | T cells, NK cells |
| Immune Checkpoint Expression | PD-L1, CTLA-4, LAG-3 expression | "Off-signal" to T cells, T cell exhaustion/anergy | T cells |
| Immunosuppressive Cytokine Secretion | TGF-β, IL-10 secretion | Inhibition of lymphocyte proliferation/function | T cells, NK cells, Macrophages |
| Recruitment of Suppressive Cells | Tregs, MDSCs, TAMs, CAFs | Direct suppression of effector cells, T cell exclusion | CTLs, NK cells, APCs, all infiltrating immune cells |
| TME Remodeling | Hypoxia, Low pH, Dense ECM | Impaired immune cell function, reduced infiltration | CTLs, all infiltrating immune cells |

## **II. Immunotherapy: Harnessing the Immune System to Fight Cancer**

Immunotherapy represents a transformative approach in cancer treatment, fundamentally shifting the paradigm from directly attacking cancer cells to empowering the patient's intrinsic immune defenses. This strategy leverages the body's natural ability to detect and eliminate abnormal cells, a process that cancer cells often manage to evade.18

### **A. Principles and Objectives of Cancer Immunotherapy**

Immunotherapy is a revolutionary type of cancer treatment that empowers the patient's own immune system to detect, recognize, and destroy cancer cells.18 While the immune system naturally surveils and attempts to eliminate abnormal cells, cancer cells often develop sophisticated ways to evade this destruction. These evasion tactics include genetic changes that make them less visible to immune cells, the expression of surface proteins that "turn off" immune cells, or alterations to the surrounding normal cells that interfere with how the immune system responds to the cancer cells.18 Immunotherapy aims to overcome these evasion strategies by boosting or enhancing the cancer-fighting capabilities of immune cells.19

The primary objectives of cancer immunotherapy are multifaceted: to educate the immune system to specifically recognize and attack cancer cells 21; to provide the body with additional components, such as proteins or antibodies, to enhance the immune response 21; to boost existing immune cells to help them more effectively eliminate cancer 21; to train the immune system to "remember" cancer cells, enabling it to target and eliminate the cancer if it returns 21; and ultimately, to revive the patient's suppressed immune system to ideally eradicate the disease.23

Immunotherapy represents a significant advancement in cancer care, offering a promising paradigm shift from traditional treatments like chemotherapy and radiation by directly treating the patient's immune system rather than solely the disease itself.21 This paradigm offers the unique advantage of immunological memory and durable responses, a distinct improvement over traditional therapies. The ability to generate immunological memory provides a potential for long-term control and prevention of recurrence that is largely absent in many conventional therapies. This implies a more sustained and potentially curative approach for a subset of patients, making immunotherapy a cornerstone of modern oncology. It has shown remarkable success, leading to impressive anti-tumor responses and long-term remissions in some patients, even for cancers previously resistant to conventional therapies.21 Its recognition as a "Scientific Breakthrough of the Year" underscores its transformative impact.19

### **B. Major Types of Immunotherapy and Their Mechanisms of Action**

Modern immunotherapy encompasses several distinct approaches, each designed to harness the immune system against cancer through specific mechanisms.

Immune Checkpoint Inhibitors (ICIs):  
ICIs are drugs that block immune checkpoints, which are normal regulatory proteins on immune cells (like T cells) or cancer cells that act as "off switches" to prevent immune responses from becoming too strong and damaging healthy tissues.16 Cancer cells exploit these checkpoints (e.g., PD-L1 on tumor cells binding to PD-1 on T cells, or CTLA-4 on T cells) to evade immune detection and destruction.10 By blocking this binding, ICIs "release the brakes" on T cells, allowing them to remain active, proliferate, and mount a stronger, more sustained anti-tumor response.16 Widely used ICIs include anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab), anti-PD-L1 antibodies, and anti-CTLA-4 antibodies (e.g., ipilimumab).16 Newer targets like LAG-3 are also being explored.16 ICIs have demonstrated significant efficacy across a broad range of cancers, including melanoma, non-small cell lung cancer (NSCLC), kidney cancer, breast cancer, bladder cancer, cervical cancer, head and neck cancer, Hodgkin lymphoma, and liver cancer.16  
Adoptive Cell Therapies (ACT):  
ACT involves collecting a patient's own immune cells, expanding or genetically modifying them outside the body (ex vivo) to enhance their cancer-fighting capabilities, and then reinfusing them back into the patient.18 These enhanced cells can then seek out and eliminate cancer cells.21 Chimeric Antigen Receptor (CAR) T-cell therapy is a prominent form of ACT where T cells are genetically engineered to express a Chimeric Antigen Receptor (CAR) on their surface.20 CARs are synthetic constructs designed to bind to specific tumor cell surface antigens (e.g., CD19 for certain leukemias and lymphomas) in an MHC-independent manner.27 Upon binding, CAR T cells are activated and mediate anti-tumoral effects through direct lysis (perforin and granzyme axis), death receptor pathways (Fas and FasL axis), and the release of cytokines.28 The process involves leukapheresis to collect T cells, laboratory modification and expansion (which can take several weeks), and subsequent reinfusion after preparatory chemotherapy.27 Tumor-Infiltrating Lymphocyte (TIL) therapy is another approach where T cells are harvested directly from a patient's tumor, expanded and activated ex vivo, and then reinfused.20  
Therapeutic Monoclonal Antibodies (mAbs):  
Monoclonal antibodies are laboratory-created immune system proteins designed to bind to specific targets (antigens) on cancer cells or immune cells.18 Their binding can disrupt cancerous activity, mark cancer cells for destruction by other immune cells (like NK cells or macrophages), block growth signals, or modulate immune checkpoints.21 Naked Monoclonal Antibodies work on their own to alert the immune system to cancer cells, flag them for destruction (e.g., Rituximab targeting CD20), or block proteins essential for cancer cell growth.33 Antibody-Drug Conjugates (ADCs) are mAbs equipped with anti-cancer drugs, allowing for targeted delivery of chemotherapy or toxins directly to tumor cells, minimizing systemic toxicity.21 Bi-specific T cell-engaging Antibodies (BiTEs) are innovative antibodies designed to bind simultaneously to a cancer cell antigen and a T cell, effectively bringing T cells into close proximity with tumor cells to enhance immune response.21 Over 90 therapeutic mAbs are currently used in oncology, alone or in combination with other agents.35 Most mAbs are administered as intravenous (IV) infusions, often in an infusion center.18 Some can be given subcutaneously.26  
Cancer Treatment Vaccines:  
Unlike preventive vaccines, cancer treatment vaccines are designed for patients who already have cancer. They work by exposing the immune system to specific tumor-associated antigens (TAAs) or modified cancer cells, stimulating an anti-tumor immune response.18 This "educates" the immune system to recognize and attack cancer cells and, crucially, to develop immunological memory to prevent recurrence.21 Vaccines can be composed of whole cancer cells (modified to be more visible), specific cancer proteins or peptides, or genetic material (DNA/RNA) from cancer cells. They may also utilize viral vectors to deliver cancer antigens.21 Some are engineered to produce immune-stimulating molecules.21 Sipuleucel-T (Provenge®) is an approved vaccine for prostate cancer, composed of a patient's own stimulated dendritic cells targeting prostatic acid phosphatase.25 Bacillus Calmette-Guérin (BCG), a weakened bacterium, is used for early-stage bladder cancer.38 T-VEC, a modified herpes simplex virus, also functions as a vaccine.38 Administration routes can vary, including intramuscular, intravenous, intradermal, intranodal, and mucosal.40  
Oncolytic Virus Therapy:  
This therapy utilizes naturally occurring or lab-modified viruses that selectively infect and replicate within cancer cells, leading to their lysis (oncolysis).20 The bursting of cancer cells releases tumor antigens and danger signals, which then stimulate a broader systemic anti-tumor immune response, potentially targeting distant tumors.42 Cancer cells often have impaired antiviral defenses, making them susceptible to these viruses.42 T-VEC (Imlygic®), a modified herpes simplex virus, is approved for melanoma. It's engineered to be less likely to infect healthy cells and to produce immune-stimulating GM-CSF protein within infected cancer cells.38 The primary delivery method for oncolytic viruses (OVs) is intratumoral injection, directly into the tumor.43 Systemic administration is a goal but faces challenges like rapid clearance by anti-virus immunity and blockade by the reticuloendothelial system (RES).43 Novel approaches for enhanced delivery include the use of nanoparticles, cell-based delivery systems, and manipulations of the tumor microenvironment to improve viral propagation.43  
Cytokine Therapy:  
Cytokines are naturally occurring proteins that act as messenger molecules, regulating the maturation, growth, and responsiveness of immune cells.21 Cytokine-based immunotherapy involves administering these proteins to modulate the host immune response towards cancer cells, enhance immune cell activation and proliferation, or directly induce tumor cell death.46 Cytokines can be broadly categorized as pro-inflammatory (e.g., TNF-α, IL-1, IL-6), which initiate immune responses, or anti-inflammatory (e.g., IL-10, TGF-β), which help reduce inflammation.48 Interleukin-2 (IL-2), for example, is used in the treatment of metastatic melanoma and renal cell carcinoma, promoting the proliferation and activation of T cells and natural killer cells, thereby enhancing anti-tumor activity.48 Interferons (IFNs) are employed in various cancers, including melanoma and certain leukemias, as they can directly inhibit tumor cell growth and modulate the immune response.47 Peginterferon alfa 2a is used for myeloproliferative neoplasms and is typically given as a subcutaneous injection.47 While promising, cytokine monotherapy at low doses may have limited results, and high doses can lead to significant side effects due to their pleiotropic effects.46 Toxicity and high production costs are also challenges associated with cytokine therapy.48  
The increasing emphasis on combination immunotherapy regimens across different modalities (e.g., ICIs with vaccines, cytokines with ICIs) reflects a growing recognition that single-agent approaches are often insufficient to overcome the multifaceted and redundant immune evasion strategies employed by cancer. Combining checkpoint inhibitors with cancer vaccines has shown promise in enhancing treatment efficacy, as evidenced by clinical trials.25 Similarly, cytokine-based combination therapies, such as combining IL-2 or IFNs with checkpoint inhibitors, aim to overcome immune suppression and enhance anti-tumor immunity.48 This trend suggests that the field is moving towards more sophisticated, synergistic treatment strategies. It acknowledges the complexity of immune evasion, where multiple pathways are often simultaneously active. Therefore, future oncology practice will likely involve personalized, multi-modal immunotherapy regimens designed to target cancer from several angles, aiming for more comprehensive and durable responses.

**Table 3: Overview of Major Immunotherapy Types and Their Mechanisms**

| Immunotherapy Type | Core Mechanism of Action | Key Examples/Targets | Primary Immune Cells Involved |
| :---- | :---- | :---- | :---- |
| Immune Checkpoint Inhibitors (ICIs) | Block inhibitory signals on T cells, "releasing the brakes" on anti-tumor immunity | Anti-PD-1 (Pembrolizumab, Nivolumab), Anti-CTLA-4 (Ipilimumab), Anti-LAG-3 | T cells |
| Adoptive Cell Therapy (ACT) \- CAR T-cell | Genetically engineer patient's T cells to express chimeric antigen receptors (CARs) that target tumor antigens | CD19-targeting CAR T cells | T cells |
| Therapeutic Monoclonal Antibodies (mAbs) | Bind to specific cancer cell targets/immune checkpoints, disrupt growth, flag for destruction, or deliver payloads | Rituximab (anti-CD20), Antibody-Drug Conjugates (ADCs), Bi-specific T cell-engaging Antibodies (BiTEs) | T cells, NK cells, Macrophages |
| Cancer Treatment Vaccines | Expose immune system to tumor-associated antigens to train it to recognize and attack cancer cells, develop memory | Sipuleucel-T, Bacillus Calmette-Guérin (BCG), T-VEC (HSV) | APCs (Dendritic Cells), T cells |
| Oncolytic Virus Therapy | Selectively infect and replicate within cancer cells, leading to lysis and release of tumor antigens to stimulate broader immune response | T-VEC (modified Herpes Simplex Virus) | Innate and Adaptive immune cells |
| Cytokine Therapy | Administer naturally occurring proteins (cytokines) to modulate, enhance, or directly induce immune cell activity against cancer | Interleukin-2 (IL-2), Interferons (IFNs) | T cells, NK cells |

### **C. Clinical Considerations in Immunotherapy**

The practical application of immunotherapy involves specific administration protocols, a multi-phased patient journey for complex therapies, and careful management of potential adverse events.

**Administration Protocols and Patient Journey:** Immunotherapy administration varies by type but frequently involves intravenous (IV) infusion.18 Some therapies, such as certain monoclonal antibodies and peginterferon, can be administered subcutaneously.26 Oncolytic viruses are primarily delivered via intratumoral injection, directly into the tumor.43 The patient journey for complex therapies like CAR T-cell therapy is multi-phased, encompassing:

* **Consultation/Workup:** This initial phase involves referral from a primary oncologist, determination of patient eligibility through review of medical history, diagnostic scans, and pathology results, and selection of a dedicated caregiver.30 Early cell collection and cryopreservation are recommended to ensure optimal sample quality for subsequent manufacturing.29  
* **Apheresis:** Once eligible, the patient undergoes leukapheresis, a procedure where blood is removed, white blood cells (including T cells) are separated, and the remaining blood components are returned to the patient.27  
* **Reprogramming/Manufacturing:** The collected T cells are then sent to a specialized manufacturing facility for genetic modification (e.g., incorporating CAR-coding viral DNA) and expansion into large batches of CAR-T cells.27 This intricate process can take several weeks.27  
* **Bridging Therapy/Lymphodepletion:** Patients may receive a short course of preparatory chemotherapy (lymphodepletion) prior to CAR T-cell infusion. This step aims to create a more favorable environment for the modified cells by reducing existing lymphocytes that could compete with the infused CAR T-cells.29  
* **Infusion:** The modified T cells are then reinfused into the patient, typically as a single infusion that usually takes less than 30 minutes.29  
* **Toxicity Monitoring and Treatment:** Following infusion, patients require close monitoring for potential adverse reactions, particularly cytokine release syndrome and neurotoxicity.30  
* **Discharge and Outpatient Follow-up:** Specialized discharge information and ongoing outpatient follow-up are crucial for managing long-term effects and monitoring disease status.30

**Efficacy and Common Applications:** Immunotherapies have demonstrated significant clinical benefits across various cancer types. Immune Checkpoint Inhibitors (ICIs) have shown impressive survival benefits in patients with melanoma, non-small cell lung cancer, kidney cancer, and other malignancies.16 Clinical responses to ICIs often correlate positively with tumor PD-L1 expression, pre-existing CD8+ T cell infiltration, and the tumor's mutational/neoantigen burden.14 CAR T-cell Therapy has proven highly effective for certain blood cancers, such as leukemias and lymphomas, even in cases where other treatments have failed.27 Oncolytic Virus Therapy can provide clinical benefits for patients with different cancer types and stages, including metastatic and incurable tumors, and is generally well-tolerated with flu-like symptoms being common side effects.44 Overall, immunotherapy has led to tumors disappearing and terminal cancers going into remission for years in some patients, revolutionizing cancer treatment.23

**Management of Immune-Related Adverse Events (irAEs):** A critical aspect of immunotherapy is the meticulous management of immune-related adverse events (irAEs), which result from the broad activation of the immune system and can range from mild to life-threatening.7 Common irAEs include fatigue, rash, pruritus, musculoskeletal pain, colitis, hepatitis, pneumonitis, endocrinopathies (e.g., hypothyroidism, type 1 diabetes, adrenal insufficiency), acute kidney injury, and myocarditis.26 Infusion reactions, characterized by fever, chills, rash, and dizziness, can also occur.26 For CAR T-cell therapy, specific irAEs include Cytokine Release Syndrome (CRS), which occurs in 70-90% of patients, typically 2-3 days post-infusion, presenting as severe flu-like symptoms (high fever, fatigue, body aches). It is generally brief (5-7 days) and effectively treated with tocilizumab.31 Another specific irAE is CAR T-cell-related Encephalopathy Syndrome (CRES), which typically starts around day 5, causing confusion, disorientation, memory loss, and sometimes speech difficulties. While distressing for patients and families, CRES is generally reversible.31

Prompt identification and management of irAEs are essential for patient safety.52 Treatment often involves withholding or permanently discontinuing therapy depending on severity.52 Systemic corticosteroids, such as high doses of prednisone or methylprednisolone (1-2 mg/kg/day), are commonly used to suppress the excessive immune response.49 Corticosteroids should be tapered slowly over at least one month to prevent worsening or recurrence of irAEs.52 Other immunosuppressants may be considered if corticosteroids are insufficient.52 Prophylactic antibiotics are recommended for patients receiving immunosuppressive therapy to prevent opportunistic infections.55 A significant challenge is that corticosteroids, while necessary for irAE management, can paradoxically reduce the effectiveness of immune checkpoint inhibitors by dampening the overall immune response.53 The inherent mechanism of immunotherapy, which relies on robust immune system activation, simultaneously creates the risk of immune-related adverse events. The standard treatment for severe irAEs, corticosteroids, can then compromise the very anti-tumor immune response that immunotherapy aims to unleash, creating a critical therapeutic dilemma. This highlights a fundamental clinical challenge in immunotherapy: achieving a delicate balance between maximizing anti-tumor immunity and minimizing autoimmune toxicity. This underscores the urgent need for more precise biomarkers to predict both response and toxicity, and for novel irAE management strategies that do not broadly suppress the anti-tumor immune response. This complexity necessitates highly individualized patient management and ongoing research into targeted irAE interventions. Research is ongoing to find ways to predict which patients will respond to immunotherapy and which will experience irAEs, using biomarkers like PD-L1 expression and tumor mutational burden.18

**Table 4: Common Immune-Related Adverse Events (irAEs) Associated with Immunotherapy**

| Organ System Affected | Common irAEs | Typical Onset/Severity (brief) | Management Strategies (brief) | Associated Immunotherapy Types |
| :---- | :---- | :---- | :---- | :---- |
| Gastrointestinal | Colitis, Diarrhea, Enteritis, Pancreatitis | Variable onset, mild to severe; can lead to perforation | Corticosteroids, cessation of therapy, supportive care, anti-TNF agents (e.g., infliximab) | ICIs |
| Endocrine | Hypothyroidism, Hyperthyroidism, Type 1 Diabetes, Adrenal Insufficiency | Variable onset, can be life-threatening; often long-term | Hormone replacement, corticosteroids (for acute inflammation) | ICIs |
| Pulmonary | Pneumonitis | Variable onset, can be severe, leading to hospitalization | Corticosteroids, cessation of therapy | ICIs |
| Hepatic | Hepatitis, Acute liver failure | Variable onset, mild to severe | Corticosteroids, cessation of therapy, supportive care | ICIs |
| Dermatologic | Rash, Pruritus, Mouth/skin sores | Variable onset, mild to severe | Topical/systemic corticosteroids, antihistamines | ICIs, mAbs |
| Neurological | CAR T-cell-related Encephalopathy Syndrome (CRES), Headache, Confusion, Disorientation | Typically \~Day 5 post-infusion (CRES); generally reversible | Corticosteroids (for CRES) | CAR T-cell |
| Cardiovascular | Myocarditis, High blood pressure, Heart failure | Variable onset, can be life-threatening | Corticosteroids, supportive care | ICIs, mAbs |
| General/Constitutional | Fatigue, Flu-like symptoms, Fever, Chills, Myalgia, Nausea, Vomiting | Often early, transient, can be severe | Supportive care (antipyretics, antiemetics), analgesics | All types (especially OV, CAR T, Cytokines) |
| Infusion Reactions | Rashes, Hives, Swelling, Flushing, Wheezing, Hypotension | During or shortly after infusion | Interrupt/slow infusion, antihistamines, corticosteroids | ICIs, mAbs |

### **D. Challenges and Future Directions in Immunotherapy**

Despite the remarkable successes achieved with immunotherapy, several significant challenges persist, underscoring the ongoing need for intensive research and development.

**Current Challenges:** Many patients either do not respond to immunotherapy at all, or they develop resistance over time, limiting the broad applicability of these treatments.10 A major hurdle is the ability to predict response; currently, only a subset of patients derives significant benefit, making it crucial to identify predictive biomarkers to select appropriate candidates and avoid unnecessary toxicity and cost.18 The management of immune-related adverse events (irAEs) remains a significant concern, as these toxicities can be severe and often require treatments that may paradoxically compromise the anti-tumor efficacy.7 The immunosuppressive nature of the Tumor Microenvironment (TME), including physical barriers (dense ECM), metabolic alterations (hypoxia, low pH), and suppressive cell populations (Tregs, MDSCs, TAMs, CAFs), continues to impede immune cell infiltration and function, representing a formidable barrier to effective therapy.10 Furthermore, the high production costs associated with certain advanced therapies, such as CAR T-cell therapy and engineered cytokines, present substantial accessibility challenges, particularly in resource-limited settings.48

**Future Directions and Emerging Trends:** Research efforts are vigorously addressing these challenges, focusing on several key areas. A prominent trend is the development of **combination therapies**, which involve testing various combinations of immune checkpoint inhibitors with other immunotherapies (e.g., cancer vaccines, cytokines), targeted therapies, or radiation therapy. The goal is to overcome resistance mechanisms and achieve synergistic anti-tumor effects.18 Another critical area is

**targeting the Tumor Microenvironment (TME)**, with strategies aimed at remodeling its immunosuppressive properties. This includes inhibiting immunosuppressive cells like TAMs and MDSCs (e.g., using CSF1R inhibitors) or targeting hypoxia and metabolic alterations within the TME (e.g., with hypoxia-activated prodrugs and metabolic inhibitors).10 The persistent challenges of immunotherapy, particularly non-response and acquired resistance, indicate a strong future trend towards highly personalized and multi-modal treatment strategies. This implies a shift from a "one-size-fits-all" approach to one that deeply integrates individual patient and tumor molecular profiles. The limited response rates and the development of resistance necessitate understanding why certain patients respond and others do not. The proposed solution is often "personalized" or "tailored" therapies based on molecular profiling.18 This signifies a move away from broad-spectrum treatments towards precision oncology in immunotherapy. Future research will heavily invest in advanced diagnostics, such as genomic sequencing and immune phenotyping of the TME, to guide treatment selection, predict efficacy, and anticipate resistance mechanisms, ultimately aiming to optimize outcomes for each individual patient.

**Personalized immunotherapy** is gaining momentum, leveraging advancements in molecular and tumor biology to profile and identify specific molecular targets. This allows for genotype-directed therapies tailored to subsets of patients, including the emerging promise of personalized cancer vaccines.23

**Engineered therapies** are also a focus, involving the design of novel immunotherapeutics with enhanced specificity and reduced toxicity, such as engineered cytokines 48 or improved viral vectors for oncolytic virotherapy.42 For therapies like oncolytic viruses, research is concentrated on overcoming systemic delivery limitations through the use of nanoparticles, cell-based delivery systems, and image-guided delivery techniques.43 Finally, continued exploration of

**novel immune checkpoint targets** beyond the established PD-1/PD-L1 and CTLA-4 pathways (e.g., LAG-3) holds promise for expanding the therapeutic landscape.16

## **III. Conclusion**

The immune system's interaction with cancer is a complex and dynamic process characterized by a continuous battle between immune surveillance and tumor immune evasion. While the immune system possesses inherent mechanisms to recognize and eliminate malignant cells through the coordinated action of innate and adaptive immune components, cancer cells are remarkably adept at developing strategies to escape these defenses. These evasion tactics include the downregulation of tumor antigens and MHC molecules, the expression of immune checkpoint molecules, the secretion of immunosuppressive cytokines, and the active remodeling of the tumor microenvironment to foster an immunosuppressive milieu. The concept of cancer immunoediting, with its phases of elimination, equilibrium, and escape, aptly describes this evolutionary arms race, highlighting the adaptive nature of cancer under immune pressure.

Immunotherapy represents a transformative advancement in oncology, shifting the focus from direct tumor ablation to empowering the patient's own immune system to fight cancer. This paradigm offers the unique advantage of immunological memory, providing the potential for durable responses and long-term disease control. Diverse immunotherapeutic modalities, including immune checkpoint inhibitors, adoptive cell therapies (such as CAR T-cell therapy and TIL therapy), therapeutic monoclonal antibodies, cancer treatment vaccines, oncolytic virus therapy, and cytokine therapy, each employ distinct mechanisms to enhance anti-tumor immunity.

Despite remarkable successes, significant challenges persist, particularly concerning patient non-response, acquired resistance, and the management of immune-related adverse events (irAEs). The inherent trade-off between robust immune activation and the risk of autoimmune toxicities, often managed with immunosuppressive corticosteroids that can blunt therapeutic efficacy, remains a critical clinical dilemma. Addressing these challenges necessitates a continued focus on understanding the intricate interplay within the tumor microenvironment and the development of more precise, personalized, and multi-modal treatment strategies. Future directions in immunotherapy are poised to integrate advanced molecular profiling to tailor therapies, develop novel engineered agents with enhanced specificity and reduced toxicity, and devise innovative combination regimens that simultaneously target multiple evasion pathways, ultimately aiming to optimize outcomes for individual patients and achieve more widespread and durable remissions.

#### **Works cited**

1. Mechanism of Immune System for Evading and Escaping Cancer Cells: A Brief Review, accessed July 1, 2025, [https://www.jmchemsci.com/article\_165149.html](https://www.jmchemsci.com/article_165149.html)  
2. Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing \- Frontiers, accessed July 1, 2025, [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01115/full](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01115/full)  
3. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy \- Frontiers, accessed July 1, 2025, [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1275904/full](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1275904/full)  
4. What Are Natural Killer Cells (NK Cells)? \- Cleveland Clinic, accessed July 1, 2025, [https://my.clevelandclinic.org/health/body/24898-natural-killer-cells](https://my.clevelandclinic.org/health/body/24898-natural-killer-cells)  
5. MicroRNAs in Cancer Immunology: Master Regulators of the Tumor Microenvironment and Immune Evasion, with Therapeutic Potential \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/2072-6694/17/13/2172](https://www.mdpi.com/2072-6694/17/13/2172)  
6. The concept of immune surveillance against tumors: The first theories \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5351698/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5351698/)  
7. Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies \- Frontiers, accessed July 1, 2025, [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1343020/full](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1343020/full)  
8. Immune surveillance of tumors \- PMC \- PubMed Central, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC1857231/](https://pmc.ncbi.nlm.nih.gov/articles/PMC1857231/)  
9. Cracking the Codes behind Cancer Cells' Immune Evasion \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/1422-0067/25/16/8899](https://www.mdpi.com/1422-0067/25/16/8899)  
10. Tumor Immune Escape Mechanisms \- Number Analytics, accessed July 1, 2025, [https://www.numberanalytics.com/blog/tumor-immune-escape-guide](https://www.numberanalytics.com/blog/tumor-immune-escape-guide)  
11. Immunosuppressive tumor microenvironments. Tumor microenvironments are composed of cellular components, extracellular matrix and interstitial fluid. Chemokines secreted from cancer cells recruit a variety of immune cells infiltrating into tumor. The interactions between cancer cells and the infiltrated immune cells determine the progression of cancer and therapeutic efficacy. Immune suppressive cells, including Treg, MDSC and M2 type TAM, limit function of the cytotoxic T cells and make tumor microenvironments immunosuppressive. Furthermore, tumor derived cytokines, like TGF-β, IL-6, etc., also suppress immune responses \- ResearchGate, accessed July 1, 2025, [https://www.researchgate.net/figure/mmunosuppressive-tumor-microenvironments-Tumor-microenvironments-are-composed-of\_fig1\_351323334](https://www.researchgate.net/figure/mmunosuppressive-tumor-microenvironments-Tumor-microenvironments-are-composed-of_fig1_351323334)  
12. Tumor Microenvironment: Immunosuppressive Cells \- R\&D Systems, accessed July 1, 2025, [https://www.rndsystems.com/product-highlights/tumor-microenvironment-immunosuppressive-cells](https://www.rndsystems.com/product-highlights/tumor-microenvironment-immunosuppressive-cells)  
13. What is Immune Evasion? \- Beckman Coulter, accessed July 1, 2025, [https://www.beckman.com/support/faq/research/what-is-immune-evasion](https://www.beckman.com/support/faq/research/what-is-immune-evasion)  
14. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5379970/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379970/)  
15. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/1422-0067/20/6/1326](https://www.mdpi.com/1422-0067/20/6/1326)  
16. Immune Checkpoint Inhibitors \- NCI, accessed July 1, 2025, [https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors)  
17. Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/2072-6694/12/11/3099](https://www.mdpi.com/2072-6694/12/11/3099)  
18. Immunotherapy for Cancer \- NCI, accessed July 1, 2025, [https://www.cancer.gov/about-cancer/treatment/types/immunotherapy](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy)  
19. Cancer immunotherapy, explained \- UChicago News \- The University of Chicago, accessed July 1, 2025, [https://news.uchicago.edu/explainer/what-is-immunotherapy](https://news.uchicago.edu/explainer/what-is-immunotherapy)  
20. Cancer Immunotherapy \- UChicago Medicine, accessed July 1, 2025, [https://www.uchicagomedicine.org/cancer/types-treatments/immunotherapy](https://www.uchicagomedicine.org/cancer/types-treatments/immunotherapy)  
21. What Is Immunotherapy? | Cancer Research Institute, accessed July 1, 2025, [https://www.cancerresearch.org/what-is-immunotherapy](https://www.cancerresearch.org/what-is-immunotherapy)  
22. Using Your Own Immune System to Fight Cancer | Stony Brook ..., accessed July 1, 2025, [https://cancer.stonybrookmedicine.edu/diagnosis-treatment/Immunotherapy](https://cancer.stonybrookmedicine.edu/diagnosis-treatment/Immunotherapy)  
23. Cancer Immunotherapy, Part 1: Current Strategies and Agents \- PMC \- PubMed Central, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5440098/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5440098/)  
24. Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/2673-5601/4/3/13](https://www.mdpi.com/2673-5601/4/3/13)  
25. Immunological Strategies to Combat Tumor Escape \- Number Analytics, accessed July 1, 2025, [https://www.numberanalytics.com/blog/immunological-strategies-combat-tumor-escape](https://www.numberanalytics.com/blog/immunological-strategies-combat-tumor-escape)  
26. Immune Checkpoint Inhibitors and Their Side Effects | American Cancer Society, accessed July 1, 2025, [https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html](https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html)  
27. CAR T-cell Therapy and Its Side Effects | American Cancer Society, accessed July 1, 2025, [https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html](https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html)  
28. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells \- PMC \- PubMed Central, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6470706/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6470706/)  
29. The Process of CAR-T Cell Therapy \- Novartis, accessed July 1, 2025, [https://www.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/process-car-t-cell-therapy](https://www.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/process-car-t-cell-therapy)  
30. Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7521122/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7521122/)  
31. Side Effects | Stanford Health Care, accessed July 1, 2025, [https://stanfordhealthcare.org/medical-treatments/c/car-t-cell-therapy/side-effects.html](https://stanfordhealthcare.org/medical-treatments/c/car-t-cell-therapy/side-effects.html)  
32. Monoclonal Antibodies: Definition & How Treatment Works \- Cleveland Clinic, accessed July 1, 2025, [https://my.clevelandclinic.org/health/treatments/22246-monoclonal-antibodies](https://my.clevelandclinic.org/health/treatments/22246-monoclonal-antibodies)  
33. Monoclonal Antibodies: What They Are & How They Treat Cancer, accessed July 1, 2025, [https://www.cityofhope.org/tests-procedures-treatments/monoclonal-antibodies](https://www.cityofhope.org/tests-procedures-treatments/monoclonal-antibodies)  
34. How Monoclonal Antibodies Treat Cancer \- YouTube, accessed July 1, 2025, [https://www.youtube.com/watch?v=dxnjAc-rqz8\&pp=0gcJCf0Ao7VqN5tD](https://www.youtube.com/watch?v=dxnjAc-rqz8&pp=0gcJCf0Ao7VqN5tD)  
35. Therapeutic Monoclonal Antibodies against Cancer: Present and Future \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10741644/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10741644/)  
36. my.clevelandclinic.org, accessed July 1, 2025, [https://my.clevelandclinic.org/health/treatments/22246-monoclonal-antibodies\#:\~:text=In%20most%20cases%2C%20monoclonal%20antibodies,getting%20treatment%20at%20one%20time.](https://my.clevelandclinic.org/health/treatments/22246-monoclonal-antibodies#:~:text=In%20most%20cases%2C%20monoclonal%20antibodies,getting%20treatment%20at%20one%20time.)  
37. www.mskcc.org, accessed July 1, 2025, [https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy/cancer-vaccines\#:\~:text=Therapeutic%20cancer%20vaccines%20expose%20your,and%20destroy%20the%20cancer%20cells.](https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy/cancer-vaccines#:~:text=Therapeutic%20cancer%20vaccines%20expose%20your,and%20destroy%20the%20cancer%20cells.)  
38. Vaccines to treat cancer | Cancer Research UK, accessed July 1, 2025, [https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs-immunotherapy/vaccines-to-treat-cancer](https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs-immunotherapy/vaccines-to-treat-cancer)  
39. Cancer Vaccines \- Cancer Research Institute, accessed July 1, 2025, [https://www.cancerresearch.org/immunotherapy-by-treatment-types/cancer-vaccines](https://www.cancerresearch.org/immunotherapy-by-treatment-types/cancer-vaccines)  
40. Vaccines in cancer treatment and prevention: the time is now \- JCI, accessed July 1, 2025, [https://www.jci.org/articles/view/195673](https://www.jci.org/articles/view/195673)  
41. pmc.ncbi.nlm.nih.gov, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6501037/\#:\~:text=Mechanisms%20of%20oncolytic%20virus%20action,the%20production%20of%20viral%20products.](https://pmc.ncbi.nlm.nih.gov/articles/PMC6501037/#:~:text=Mechanisms%20of%20oncolytic%20virus%20action,the%20production%20of%20viral%20products.)  
42. Oncolytic Virus Therapy \- Cancer Research Institute, accessed July 1, 2025, [https://www.cancerresearch.org/immunotherapy-by-treatment-types/oncolytic-virus-therapy](https://www.cancerresearch.org/immunotherapy-by-treatment-types/oncolytic-virus-therapy)  
43. Emerging delivery strategy for oncolytic virotherapy \- PMC \- PubMed Central, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11153257/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11153257/)  
44. What Are the Side Effects of Oncolytic Virus Therapy? \- YouTube, accessed July 1, 2025, [https://www.youtube.com/watch?v=O54kZ9yJFHU](https://www.youtube.com/watch?v=O54kZ9yJFHU)  
45. Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5687448/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5687448/)  
46. Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy, accessed July 1, 2025, [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00402/full](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00402/full)  
47. Cytokines | Immunotherapy \- Cancer Research UK, accessed July 1, 2025, [https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs-immunotherapy/cytokines](https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs-immunotherapy/cytokines)  
48. Cytokine Therapy in Oncology Graduate Programs \- Number Analytics, accessed July 1, 2025, [https://www.numberanalytics.com/blog/cytokine-therapy-oncology-graduate-programs](https://www.numberanalytics.com/blog/cytokine-therapy-oncology-graduate-programs)  
49. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study \- PMC \- PubMed Central, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6436564/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6436564/)  
50. What are the considerations and treatment options for immunotherapy?, accessed July 1, 2025, [https://www.droracle.ai/articles/153531/immunotherapy](https://www.droracle.ai/articles/153531/immunotherapy)  
51. Efficacy and adverse reaction management of oncolytic viral intervention combined with chemotherapy in patients with liver metastasis of gastrointestinal malignancy, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10183573/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10183573/)  
52. Preparation, Storage and Administration of KEYTRUDA® (pembrolizumab) | HCP, accessed July 1, 2025, [https://www.keytrudahcp.com/dosing/preparation-storage-administration/](https://www.keytrudahcp.com/dosing/preparation-storage-administration/)  
53. Researchers Tackle Immune-related Adverse Effects \- Cancer Today, accessed July 1, 2025, [https://www.cancertodaymag.org/cancer-talk/researchers-tackle-immune-related-adverse-effects/](https://www.cancertodaymag.org/cancer-talk/researchers-tackle-immune-related-adverse-effects/)  
54. Side Effects of CAR T-Cell Therapy | Rutgers Cancer Institute, accessed July 1, 2025, [https://cinj.org/patient-care/side-effects-car-t-cell-therapy](https://cinj.org/patient-care/side-effects-car-t-cell-therapy)  
55. HEY Guidelines for the management of Toxicities associated with immune checkpoint inhibitors., accessed July 1, 2025, [https://www.hey.nhs.uk/wp/wp-content/uploads/2018/02/immuneCheckpointInhibitors.pdf](https://www.hey.nhs.uk/wp/wp-content/uploads/2018/02/immuneCheckpointInhibitors.pdf)